EUVIMEDDescubrir EUVIMED
Open access

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors

Edoardo Cammarata, Chiara Airoldi, Jacopo Colombo, Andrealuna Ucciero, Luca Mastorino, Veronica Arese, Lorenza Burzi, Franco Castelli, Massimo Chiarpenello, Francesca Graziola, Claudia Leporati, Michela Ortoncelli and 9 more

Dermatology Practical & Conceptual · 2026-07-31 · 16 (3) · 6747

DOI: 10.5826/dpc.1603a6747 ↗

At a glance

Journal article in Dermatology Practical & Conceptual, published online on 2026-07-31. Written by Edoardo Cammarata and 20 co-authors. Institution: SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy. Cited 1 times so far (Crossref); 22 references. The full text is freely available in PubMed Central.

ResumenDatos bibliográficosCiteRelated studies

Abstract (original language)

Introduction

Chronic plaque psoriasis is commonly treated with IL-17 and IL-23 inhibitors, which are highly effective but associated with substantial costs. Because many patients achieve long-term disease control, fixed-dose regimens may result in overtreatment.

Objectives

This study assessed the economic impact of disease-activity-guided dose reduction (DR) strategies using secukinumab, brodalumab, guselkumab, and risankizumab in adults with stable plaque psoriasis.

Methods

This cost analysis was based on data from the PSORED trial, a multicenter prospective open-label study conducted in Piedmont, Italy (2023–2025). Patients with stable disease (PASI ≤3, DLQI ≤3 for ≥9 months) underwent DR trough a 1.5x extension of maintenance dosing intervals. Costs under DR and standard dosing (SD) were compared over 52 weeks using Italian tariff data and real-world treatment patterns.

Results

Among 156 enrolled patients, 39 discontinued DR, 38 returned to standard dosing, and one switched therapy. DR reduced biologics consumption without increasing follow-up requirements, yielding a 26% decrease in total costs and an average annual saving of €7,303.57 per patient.

Conclusions

DR was both clinically effective and cost-saving, maintaining disease control without major safety concerns. These findings support the implementation of DR strategies in routine clinical practice to enhance long-term sustainability while preserving therapeutic efficacy.

Authors and institutions

  • SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy.
  • Hospital Pharmacy, AOU Maggiore della Carità, Novara, Italy.
  • Dermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
  • SSD Dermatologia, AO Santa Croce e Carle Hospital, Cuneo, Italy.
  • SS Dermatologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • UO Dermatologia, Ospedale Koelliker, Torino, Italy.

Cite

APA

Cammarata, E., Airoldi, C., Colombo, J., Ucciero, A., Mastorino, L., Arese, V., Burzi, L., Castelli, F., Chiarpenello, M., Graziola, F., Leporati, C., Ortoncelli, M., Pella, P., Pertusi, G., Pisterna, A., Quaglino, P., Ribero, S., Rossotto, G., Tiberio, R., …, & Savoia, P. (2026). Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. Dermatology Practical & Conceptual, 16(3), 6747. https://doi.org/10.5826/dpc.1603a6747

Vancouver

Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, et al. Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. Dermatology Practical & Conceptual. 2026;16(3):6747. doi:10.5826/dpc.1603a6747

BibTeX
@article{Cammarata2026,
  author = {Cammarata, Edoardo and Airoldi, Chiara and Colombo, Jacopo and Ucciero, Andrealuna and Mastorino, Luca and Arese, Veronica and Burzi, Lorenza and Castelli, Franco and Chiarpenello, Massimo and Graziola, Francesca and Leporati, Claudia and Ortoncelli, Michela and Pella, Paolo and Pertusi, Ginevra and Pisterna, Alessia and Quaglino, Pietro and Ribero, Simone and Rossotto, Gianluca and Tiberio, Rossana and Dapavo, Paolo and Savoia, Paola},
  title = {Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors},
  journal = {Dermatology Practical & Conceptual},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {6747},
  doi = {10.5826/dpc.1603a6747}
}
Start for free →